MKS Instruments Declares Quarterly Cash Dividend

ANDOVER, Mass., May 08, 2024 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on June 7, 2024, to Read more

MKS Instruments Declares Quarterly Cash Dividend

ANDOVER, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on March 8, 2024, to Read more

Xylem Reports Fourth-Quarter and Full-Year 2023 Results

Fourth-Quarter Highlights Orders of $2.0 billion , up 42% on a reported basis and 10% organically Revenue of $2.1 billion , up 41% on a reported basis and 9% organically Earnings per share of $1.10 , up 34%; $0.99 on an adjusted basis, down 1% Full-Year Highlights Revenue of $7.4 billion , up 33% Read more

MKS Instruments Commits to Reduce Carbon Emissions

Targets 42% reduction of combined scope 1 and 2 carbon emissions by 2030 ANDOVER, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that it has committed to reduce its combined Scope 1 Read more

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1 The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium... Read more